Endocrinology and Metabolism

Review Article

Diabetes, obesity and metabolism
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis: Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung; Endocrinol Metab. 2023;38(4):359-372. Published online July 24, 2023; DOI: https://doi.org/10.3803/EnM.2023.1764

14,900 View
761 Download
17 Web of Science
25 Crossref

When sodium-glucose cotransporter-2 (SGLT2) inhibitors were first introduced a decade ago, no one expected them to have substantial effects beyond their known glucose-lowering effects, until the emergence of evidence of their robust renal and cardiovascular benefits showing that they could attenuate progression of kidney disease, irrespective of diabetes, as well as prevent the development of acute kidney injury. Still, the precise and elaborate mechanisms underlying the major organ protection of SGLT2 inhibitors remain unclear. SGLT2 inhibitors inhibit the reabsorption of sodium and glucose in the proximal tubule of the kidney and then recovers tubuloglomerular feedback, whereby SGLT2 inhibitors reduce glomerular hyperfiltration. This simple demonstration of their beneficial effects has perplexed experts in seeking more plausible and as yet undisclosed explanations for the whole effects of SGLT2 inhibitors, including metabolism reprogramming and the modulation of hypoxia, inflammation, and oxidative stress. Given that the renal benefits of SGLT2 inhibitors in patients with kidney disease but without diabetes were comparable to those seen in patients with diabetes, it may be reasonable to keep the emphasis on their hemodynamic actions. In this context, the aim of the present review is to provide a comprehensive overview of renal hemodynamics in individuals with diabetes who are treated with SGLT2 inhibitors, with a focus on natriuresis associated with the regulation of tubuloglomerular feedback and potential aquaresis. Throughout the discussion of alterations in renal sodium and water transports, particular attention will be given to the potential enhancement of adenosine and its receptors following SGLT2 inhibition.

Citations

Citations to this article as recorded by

Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
Diabetes, Obesity and Metabolism.2026; 28(3): 1764. CrossRef
Molecular mechanisms of PCSK9 in cardiology: therapeutic implications and clinical impacts on the cardiorenal axis
Sandeep Kaur, Drishti Panjwani, Shareen Singh, Souvik Banerjee, Sukriti Wadehra, Amritpal Kaur, Thakur Gurjeet Singh
Molecular and Cellular Biochemistry.2026;[Epub] CrossRef
Hepatorenal vulnerability flagged by glomerular hyperfiltration in metabolic liver disease: a large health-screening cohort evidence
Dae-Jeong Koo, Yun Tae Kim, Sun-Joon Moon, Hyemi Kwon, Se Eun Park, Sang Min Lee, Cheol-Young Park, Won-Young Lee, Sung Rae Cho, Eun-Jung Rhee
Diabetology & Metabolic Syndrome.2026;[Epub] CrossRef
Effects of SGLT2 inhibitors on NSAID-associated acute kidney injury in type 2 diabetes: a claims-based cohort study
Yuki Kunitsu, Hiroyoshi Koide, Keiko Ikuta, Daiki Hira, Shunsaku Nakagawa, Masahiro Tsuda, Shin-Ya Morita, Tomohiro Terada
BMC Nephrology.2026;[Epub] CrossRef
Redefining SGLT2 inhibitors through cytoprotective mechanisms
Sanja Stankovic, Zoran Miloradovic, Vladimir Petrovic, Milan Stoiljkovic
European Journal of Pharmacology.2026; 1016: 178647. CrossRef
Analysis of the Endocrine Responses to Anti-Diabetes Drugs: An Issue of Elevated Plasma Renin Concentration in Sodium-Glucose Co-Transporter 2 Inhibitor
Cheng-Wei Lin, Shih-Yuan Hung, I-Wen Chen
International Journal of General Medicine.2025; Volume 18: 135. CrossRef
Advances in understanding and managing diabetic kidney disease: An updated review
Elmukhtar Habas, Amnna Rayani, Aml Habas, Kalifa Farfar, Eshrak Habas, Khaled Alarbi, Ala Habas, Elmehdi Errayes, Gamal Alfitori
Ukrainian Journal of Nephrology and Dialysis.2025; (1(85)): 66. CrossRef
Dietary Polyunsaturated Fatty Acid Deficiency Impairs Renal Lipid Metabolism and Adaptive Response to Proteinuria in Murine Renal Tubules
Yaping Wang, Pan Diao, Daiki Aomura, Takayuki Nimura, Makoto Harada, Fangping Jia, Takero Nakajima, Naoki Tanaka, Yuji Kamijo
Nutrients.2025; 17(6): 961. CrossRef
Diuretics: a review of the pharmacology and effects on glucose homeostasis
Mauricio Di Fulvio, Yakshkumar Dilipbhai Rathod, Shorooq Khader
Frontiers in Pharmacology.2025;[Epub] CrossRef
SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology
Alessandra Greco, Maria Laura Canale, Vincenzo Quagliariello, Stefano Oliva, Andrea Tedeschi, Alessandro Inno, Marzia De Biasio, Irma Bisceglia, Luigi Tarantini, Nicola Maurea, Alessandro Navazio, Marco Corda, Attilio Iacovoni, Furio Colivicchi, Massimo G
International Journal of Molecular Sciences.2025; 26(10): 4780. CrossRef
Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)
Amin Roshdy Soliman, Mohamed Elkhatib, Sahier El-Khashab, Rasha Ahmed Darwish, Ahmed Fayed, Tarek S. Abdelaziz, Hany Hammad, Rabab Mahmoud Ahmed, Hoda Abdelhamid Maamoun
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Cardiovascular and Renal Outcomes Following Repeated Naringenin Exposure in Normotensive and Hypertensive Rats
Anelize Dada, Rita de Cássia Vilhena da Silva, Mariana Zanovello, Anelise Felício Macarini, Thaise Boeing, Valdir Cechinel Filho, Priscila de Souza
Pharmaceuticals.2025; 18(6): 873. CrossRef
Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
Tabitha Kusi-Yeboah, Isaac Gianfrancesco, Muzammil Arif Din Abdul Jabbar, Phoebe Collins, Dalton James Bally, Juliet Thornton, Kieran Williams, Ayoola Ishola, Lucy Hong, Ping Jing Toong, Milindu Wickramarachchi
Frontiers in Cardiovascular Medicine.2025;[Epub] CrossRef
Sodium-glucose co-transporter 2 inhibitor-induced increase in adenosine promotes lipolysis and weight reduction by activating reno-adipose autonomic neurocircuitry
Aika Hagiwara, Shintaro Yamaguchi, Kazutoshi Miyashita, Kenichiro Kinouchi, Kaori Hayashi, Hiroshi Itoh
Hypertension Research.2025; 48(10): 2664. CrossRef
Chronic kidney disease in the primary care setting: A narrative review
Faryal Safdar, Ahsan Aslam
Journal of General and Family Medicine.2025; 26(5): 385. CrossRef
Determining the role of SGLT2 inhibitors (dapagliflozin) on progression of proteinuria among non-diabetic adult patients with chronic kidney disease: a randomized controlled trial
Shivam Srivastava, Saurabh Agarwal, Yuvraj Gulati, Alok Kumar Singh, Prakhar Aggarwal
International Journal of Advances in Medicine.2025; 12(6): 553. CrossRef
2025 Taiwan consensus recommendations for primary care of chronic kidney disease
Yi-Chun Tsai, Pei-Yu Wu, Tai-Shuan Lai, Chih-Chien Sung, Yi-Wen Chiu, Shang-Jyh Hwang, Yung-Ho Hsu, Mai-Szu Wu, Chung-Liang Shih
Journal of the Formosan Medical Association.2025;[Epub] CrossRef
Bridging Cardiorenal and Hepatic Disease: The Emerging Role of SGLT2 Inhibitors in Cirrhosis
Omar Alkasabrah, Sameeha Ibrahim, Abdullah Hafeez, Muhammad Qasim Chaudhry, Faiza Jajja, Maharshi Raval, Hritvik Jain, Darshil Maheta, Siddharth Pravin Agrawal, William H. Frishman, Wilbert S. Aronow
Cardiology in Review.2025;[Epub] CrossRef
Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial
Bassant M. Mahboub, Ayman F. Refaie, Sahar M. El-Haggar, Yasser M. Hafez, Tarek M. Mostafa
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Results from a cross-specialty consensus on optimal management of patients with chronic kidney disease (CKD): from screening to complications
Mustafa Arici, Samir Helmy Assaad-Khalil, Marcello Casaccia Bertoluci, Jason Choo, Yau-Jiunn Lee, Magdalena Madero, Guillermo Javier Rosa Diez, Vicente Sánchez Polo, Sungjin Chung, Teerawat Thanachayanont, Carol Pollock
BMJ Open.2024; 14(3): e080891. CrossRef
Chronic Kidney Disease and SGLT2 Inhibitors
Eun Sil Koh, Sungjin Chung
The Journal of Korean Diabetes.2024; 25(1): 16. CrossRef
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Veraprapas Kittipibul, Zachary L. Cox, Supavit Chesdachai, Mona Fiuzat, JoAnn Lindenfeld, Robert J. Mentz
Journal of the American College of Cardiology.2024; 83(16): 1568. CrossRef
Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
Ivana Jurin, Vanja Ivanović Mihajlović, Zrinka Šakić, Marin Pavlov, Tomislav Šipić, Petra Vitlov, Hrvoje Falak, Danijela Grizelj, Šime Manola, Mario Udovičić
Journal of Cardiovascular Development and Disease.2024; 11(11): 364. CrossRef
Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review
Roxana Brata, Andrei Vasile Pascalau, Ovidiu Fratila, Ioana Paul, Mihaela Mirela Muresan, Andreea Camarasan, Tiberia Ilias
Healthcare.2024; 12(23): 2464. CrossRef
Synopsis of the Korean Society of Nephrology 2023 Practical Recommendations for the Management of Diabetic Kidney Disease
Sungjin Chung
The Korean Journal of Medicine.2023; 98(6): 270. CrossRef

Original Article

Clinical Study
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim; Endocrinol Metab. 2020;35(2):329-338. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.329

11,160 View
269 Download
16 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D).
Methods
This was a 6-month retrospective case-control study in subjects with uncontrolled T2D (glycated hemoglobin [HbA1c] >7%) on conventional treatment. The study group started add-on therapy with empagliflozin (10 mg once a day) while the control group was up-titrated with existing medication, using either monotherapy or a combination of metformin, sulfonylurea, and a dipeptidyl peptidase-4 inhibitor. The primary endpoints included changes in HbA1c, fasting plasma glucose (FPG), and 2-hour postprandial glucose (PP2) levels. Secondary outcomes included changes in body composition, body mass index (BMI), and serum ketone bodies, and urinary excretion of sodium, potassium, chlorine, calcium, phosphorus, and glucose.
Results
After treatment, the reduction in HbA1c was significantly greater in the empagliflozin group than in controls (from 8.6%±1.6% to 7.6%±1.5% vs. 8.5%±1.1% to 8.1%±1.1%; P<0.01). Similar patterns were found in FPG and PP2 levels. Empagliflozin decreased systolic and diastolic blood pressure, triglycerides, and alanine and aspartate aminotransferase levels. Body weight, BMI, waist circumference, fat mass, and abdominal visceral fat area decreased significantly while lean body mass was maintained. Total ketones, β-hydroxybutyrate, and acetoacetate levels increased significantly after empagliflozin.
Conclusion
In addition to glucose lowering, an empagliflozin add-on regimen decreased blood pressure and body fat, and improved metabolic profiles significantly. Empagliflozin add-on is superior to dose escalation in patients with T2D who have inadequate glycemic control on standard medications.

Citations

Citations to this article as recorded by

Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study
Soo Lim, Cheol Young Park, In Kyung Jeong, Ji Sung Yoon, Sang Yong Kim, Eun Seok Kang, Junghyun Noh, Kyu Yeon Hur, Sungrae Kim
Journal of Diabetes and its Complications.2026; 40(1): 109214. CrossRef
Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Fatemeh Moosaie, Shiva Abedinzadeh, Soghra Rabizadeh, Kimia Daneshvar, Mohammadamin Noorafrooz, Fatemeh Alsadat Mojtahedi, Niloofar Deravi, Seyede Marzie Fatemi Abhari, Akam Ramezani, Alipasha Meysamie, Marzieh Hajibabaei, Sahar Karimpour Reyhan, Mahsa Ab
Scientific Reports.2025;[Epub] CrossRef
SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients
Mihaela-Simona Popoviciu, Teodor Salmen, Delia Reurean-Pintilei, Vlad Voiculescu, Anca Pantea Stoian
Medicina.2025; 61(3): 548. CrossRef
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Jessica Chadwick, Colin Berry, Meredith A. Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A. Hinterberg, Rury R. Holman, Matthew M.Y. Lee, Torbjørn Omland, Clare Paterson, Mark C. Petrie, Naveed Sattar, Svati H. Shah, Sama Shrestha, Harald Sourij, E
The Journal of Clinical Pharmacology.2025; 65(11): 1460. CrossRef
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Yong-ho Lee, Soo Lim, Melanie J. Davies
Nature Reviews Endocrinology.2025; 21(12): 783. CrossRef
Literature Review on the Effects of Functional Food Ingredients for Blood Glucose and Body Fat Reduction on Glycemic Control in Insulin Resistance and Diabetes
Nohyeon Kim, Minhee Lee, Yoo Kyung Park, Jeongmin Lee
Journal of the Korean Society of Food Science and Nutrition.2025; 54(10): 805. CrossRef
Independent association of thigh muscle fat density with vascular events in Korean adults
Hun Jee Choe, Won Chang, Matthias Blüher, Steven B. Heymsfield, Soo Lim
Cardiovascular Diabetology.2024;[Epub] CrossRef
Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
Minji Sohn, Seoungyeon Nam, Michael A. Nauck, Soo Lim
BMC Medicine.2024;[Epub] CrossRef
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas
Irish Journal of Medical Science (1971 -).2022; 191(4): 1647. CrossRef
A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat
Min Hee Lee, Ian J. Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Craig R. Malloy, Eunsook S. Jin
Metabolism Open.2022; 13: 100161. CrossRef
Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects
Soo Lim, Minji Sohn, Yujin Shin, Ele Ferrannini
Diabetes, Obesity and Metabolism.2022; 24(4): 757. CrossRef
Correlation of dynamic membrane fluctuations in red blood cells with diabetes mellitus and cardiovascular risks
Minji Sohn, Ji Eun Lee, MinGeun Ahn, YongKeun Park, Soo Lim
Scientific Reports.2021;[Epub] CrossRef
Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study
Yujin Shin, Haeri Choi, Soo Lim
Diabetes Research and Clinical Practice.2021; 175: 108843. CrossRef
Impact of COVID-19 and Associated Preventive Measures on Cardiometabolic Risk Factors in South Korea
Minji Sohn, Bo Kyung Koo, Ho Il Yoon, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Soo Lim
Journal of Obesity & Metabolic Syndrome.2021; 30(3): 248. CrossRef

First
Prev
Page of 1
Next
Last

Search